Treatment with the synthetic PPARγ ligand rosiglitazone induced different changes of SOX9 and β-catenin expression and subcellular localization in the colon cancer cell lines Caco2, SW480, HCT116, and HT29. This evidence concerns the gene SOX9 and malignant colon neoplasm.